Vorolanib plus cadonilimab for untreated advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two new drugs, vorolanib and cadonilimab, for people with advanced kidney cancer that hasn't been treated before. The combination aims to shrink tumors and slow down the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with clear cell renal cell carcinoma, a common type of kidney cancer.
- Your cancer must be advanced (can't be removed with surgery) or have spread to other parts of the body (Stage IV).
- You must not have had any prior treatment for kidney cancer (except certain types of adjuvant or neoadjuvant therapy).
- You should be between 18 and 75 years old.
- You need to be generally healthy enough to carry out daily activities (KPS score of 70 or higher).
- Your blood counts and organ functions must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This trial tests a combination of two drugs — voronib and everolimus — for people with clear cell kidney cancer whose previous targeted therapy and immunotherapy have stopped working. The goal is to see if this new combination can help when other treatments have failed.
This trial compares two new treatment options for advanced kidney cancer (clear cell type) that has worsened after immunotherapy. One group gets two oral drugs (vorolanib and everolimus) together; the other gets a standard targeted therapy (sunitinib).
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.